Modern Approaches to the Eradication of Helicobacter pylori: A Spectrum of Perspectives



如何引用文章

全文:

详细

Helicobacter pylori (H. pylori) is one of the most common infections detected in approximately 50% of the global population. The Russian Federation is among the regions with a relatively high prevalence of H. pylori. Currently, eradication therapy is the main strategy not only for the treatment and prevention of gastrointestinal diseases but also for reducing the risk of developing stomach cancer, highlighting the medical and social significance of this infection. The main reason for the decreased effectiveness of therapy is recognised worldwide as the primary or secondary resistance of the microorganism to antibacterial drugs. It is generally accepted that adapting national treatment regimens for H. pylori infection based on systematic testing for antimicrobial sensitivity is necessary to limit the growth of global antibiotic resistance. Despite decades of research and clinical practice, finding the most effective, safe, and simple therapy remains a significant challenge for clinicians.

This review provides a comparative analysis of current recommendations for the treatment of H. pylori infection presented by various national and regional gastroenterological societies, including those currently relevant in the Russian Federation.

全文:

受限制的访问

作者简介

Inna Oganezova

North-Western State Medical University named after I.I. Mechnikov, St. Petersburg

编辑信件的主要联系方式.
Email: oganezovaia@gmail.com
ORCID iD: 0000-0003-0844-4469

д-р мед. наук, профессор кафедры пропедевтики внутренних болезней, гастроэнтерологии и диетологии имени С.М. Рысса

俄罗斯联邦, 191015, Russian Federation, Saint-Petersburg, Kirochnaya street, 41

Liya Belousova

North-Western State Medical University named after I.I. Mechnikov

Email: liya-belousova@yandex.ru
ORCID iD: 0000-0003-4778-1767

кандидат медицинских наук, доцент, кафедра пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса

俄罗斯联邦, 191015, Russian Federation, Saint-Petersburg, Kirochnaya street, 41

Igor Bakulin

North-Western State Medical University named after I.I. Mechnikov

Email: igbakulin@yandex.ru
ORCID iD: 0000-0002-6151-2021

доктор медицинских наук, профессор, заведующий кафедрой пропедевтики внутренних болезней, гастроэнтерологии и диетологии им. С.М. Рысса

俄罗斯联邦, 191015, Russian Federation, Saint-Petersburg, Kirochnaya street, 41

参考

  1. Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022
  2. Bordin D, Morozov S, Plavnik R, et al. Helicobacter pylori infection prevalence in ambulatory settings in 2017-2019 in RUSSIA: The data of real-world national multicenter trial. Helicobacter. 2022;27(5):e12924. doi: 10.1111/hel.12924
  3. Zakcharova NV, Simanenkov VI, Bakulin IG, at al. Prevalence of Helicobacter pylori infection in gastroenterological patients in St. Petersburg. Farmateka. 2016;5:33-39. (In Russ)
  4. Bakulina N.V., Simanenkov V.I., Bakulin I.G., Ilchishina T.A. Рrevalence of Нelicobacter pylori infection among physicians. Experimental and Clinical Gastroenterology. 2017;(12):20-24.
  5. Ansari S, Yamaoka Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins (Basel). 2019;11(11):677. doi: 10.3390/toxins11110677
  6. Bordin D, Shengelia MI, Ivanova VA, Voynovan IN. Helicobacter pylori: clinical significance and diagnostic principles. Infectious diseases: News, Opinions, Training. 2022;11:119-129. doi.10.33029/2305-3496-2022-11-1-119-129.
  7. Venerito M, Schneider C, Costanzo R, Breja R, Röhl FW, Malfertheiner P. Contribution of Helicobacter pylori infection to the risk of peptic ulcer bleeding in patients on nonsteroidal anti-inflammatory drugs, antiplatelet agents, anticoagulants, corticosteroids and selective serotonin reuptake inhibitors. Aliment Pharmacol Ther. 2018;47(11):1464-1471. doi.org/10.1111/apt.14652
  8. Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-1367. doi: 10.1136/gutjnl-2015-309252
  9. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017 [published correction appears in Lancet Gastroenterol Hepatol. 2020 Mar;5(3):e2. doi: 10.1016/S2468-1253(20)30020-0]. Lancet Gastroenterol Hepatol. 2020;5(1):42-54. doi: 10.1016/S2468-1253(19)30328-0
  10. Voynovan IN, Embutnieks YuV, Mareeva DV, Kolbasnikov SV, Bordin DS. Helicobacter pylori as a risk factor for gastric cancer: the evidence and primary prevention strategy. Almanac of Clinical Medicine. 2019;47(6):535–47. doi: 10.18786/2072-0505-2019-47-052.
  11. Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2019;22(3):435–45. doi.org/10.1007/s10120-018-0876-0
  12. Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106(7):dju116. doi: 10.1093/jnci/dju116
  13. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388. doi: 10.1055/a-0859-1883
  14. Ivashkin VT, Mayev IV, Kaprin AD, et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53-74. (In Russ.) doi.org/10.22416/1382-4376-2019-29-5-53-74
  15. Nyssen OP, Bordin D, Tepes B, et al. Hp-EuReg Investigators. European Registry on Helicobacter pylori management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut. 2021;70(1):40-54. doi.org/10.1136/gutjnl-2020-321372
  16. Nyssen OP, Vaira D, Tepes B, et al. Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg). J Clin Gastroenterol. 2022;56(2):e98-e108. doi.org/10.1097/MCG.0000000000001482
  17. Bakulina NV, Maev IV, Savilova IV, et al. Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β. Terapevticheskii arkhiv. 2019;91(8):34-40. doi: 10.26442/00403660.2019.08.000380
  18. Li M, Gao N, Wang S, Guo Y, Liu Z. Bibliometric analysis of Helicobacter pylori resistance-from 2002 to 2022. Helicobacter. 2023;28(4):e12983. doi: 10.1111/hel.12983
  19. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of Antibiotic Resistance in Helicobacter pylori: ASystematic Review and Meta-analysis in World Health Organization Regions. Gastroenterology. 2018;155(5):1372-1382.e17. doi.org/10.1053/j.gastro.2018.07.007
  20. Andreev DN, Maev IV, Kucheryavyy YA. Ter Arkh. 2020;92(11):24-30. Published 2020 Dec 26. doi.org/10.26442/00403660.2020.11.000795
  21. Ji YH, Shi YM, Hei QW, et al. Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection. Helicobacter. 2023 Feb;28(1):e12937. doi.org/10.1111/hel.12937
  22. Ivashkin V.T., Lapina T.L., Maev I.V., et al. Clinical Practice Guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for H. pylori Diagnostics and Treatment in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72-93. doi.org/10.22416/1382-4376-2022-32-6-72-93
  23. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212-239. doi.org/10.1038/ajg.2016.563
  24. Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review. Gastroenterology. 2021;160(5):1831-1841. doi.org/10.1053/j.gastro.2020.11.059
  25. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. Published online August 8, 2022. doi: 10.1136/gutjnl-2022-327745
  26. Ding SZ, Du YQ, Lu H. et al. National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology, and Chinese Alliance for Helicobacter pylori Study. Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut. 2022;71(2):238-253. doi.org/10.1136/gutjnl-2021-325630
  27. Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019;24(4):e12597. doi.org/10.1111/hel.12597
  28. Jung HK, Kang SJ, Lee YC, et al. Korean College of Helicobacter and Upper Gastrointestinal Research. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15(2):168-195. doi.org/10.5009/gnl20288
  29. Alsohaibani F, Peedikayil M, Alshahrani A, et al. Practice guidelines for the management of Helicobacter pylori infection: The Saudi H. pylori Working Group recommendations. Saudi J Gastroenterol. 2022;10.4103/sjg.sjg_288_22. https://doi.org/10.4103/sjg.sjg_288_22
  30. Kasahun GG, Demoz GT, Desta DM. Primary Resistance Pattern of Helicobacter pylor to Antibiotics in Adult Population: A Systematic Review. Infect Drug Resist. 2020 May 28;13:1567-1573. doi.org/10.2147/IDR.S250200
  31. Hu Y, Zhu Y, Lu NH. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci. 2017 May;62(5):1146-1154. doi.org/10.1007/s10620-017-4536-8
  32. Lee JH, Ahn JY, Choi KD, et al. Korean College of Helicobacter; Upper Gastrointestinal Research. Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study. Helicobacter. 2019 Aug;24(4):e12592. doi.org/10.1111/hel.12592
  33. Shih CA, Shie CB, Hsu PI. Update on the first-line treatment of Helicobacter pylori infection in areas with high and low clarithromycin resistances. Therap Adv Gastroenterol. 2022;15:17562848221138168. doi.org/10.1177/17562848221138168
  34. Ko SW, Kim Y-J, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: Systemic review and meta-analysis. Helicobacter. 2019;e12565. https://doi.org/10.1111/hel.12565
  35. McNicholl AG, Bordin DS, Lucendo A, et al. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90 % of Patients. Clin Gastroenterol Hepatol. 2020;18(1):89–98. doi.org/10.1016/j.cgh.2019.03.048
  36. Han Z, Li Y, Kong Q, et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022 Dec;27(6):e12930. doi.org/10.1111/hel.12930
  37. Mori H, Suzuki H. Update on quinolone-containing rescue therapies for Helicobacter pylori infection. World J Gastroenterol. 2020 Apr 21;26(15):1733-1744. doi.org/10.3748/wjg.v26.i15.1733
  38. Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases. 2022 Jul 6;10(19):6349-6359. doi.org/10.12998/wjcc.v10.i19.6349

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 70763 от 21.08.2017 г.


##common.cookie##